AbbVie Says 20% Of U.S. Managed Care Lives Covered Exclusively By Viekira Pak
This article was originally published in The Pink Sheet Daily
Executive Summary
Formulary decisions for HCV agents are occurring rapidly since Viekira’s approval, with AbbVie saying it currently has access to about 40% of U.S. managed care lives. Gilead and AbbVie likely will take patients from each other’s exclusive formulary positions, however, due to labeling differences for Harvoni and Viekira.
You may also be interested in...
FDA To Ramp Up ASCA Pilot In 2021
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
Scotland's MGB Plots Phase III For Promising Antibacterial
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AstraZeneca Vaccine May Only Gain EU Approval In Under 70s
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: